TLR2 and renal cell carcinoma: TLR2/4 are dominant in gastrointestinal cancers, like esophageal cancer, GC, and colon cancer, while TLR9 signaling is more common in other kinds of cancers, like breast cancer, prostate cancer, and renal cell carcinoma (34).